The diagnostic and prognostic value of plasma microRNA‑125b‑5p in patients with multiple myeloma

Abstract

Abstract. Aberrant expression of microRNAs (miRNAs) contributes to the progression and outcomes of several types of tumor, while circulating miRNAs have been reported to act as biomarkers for several types of cancer. To identify specific circulating miRNAs associated with multiple myeloma (MM), a miRNA microarray analysis was used, which identified 8 upregulated miRNAs and 4 downregulated miRNAs in the plasma of 6 patients with MM compared with 6 healthy individuals. Based on the microarray results, the 8 miRNAs (miR-125b-5p, miR-483-3p, miR-4326, miR-6894-3p, miR-4498, miR-490-3p, miR-7155-5p and miR-937-3p), which were notably upregulated in MM patients were chosen for a second clinical study in 20 healthy controls and 35 patients with MM using reverse transcription-quantitative polymerase chain reaction. Receiver operating characteristic analysis demonstrated that miR-125b-5p and miR-490-3p displayed considerable diagnostic accuracy for MM with areas under the curve of 0.954 (P<0.001) and 0.866 (P=0.028), respectively. In addition, the plasma level of miR-125b-5p was associated with the international staging system disease stage. Patients with higher levels of plasma miR-125b-5p had a significantly shorter event-free survival. However, miR-490-3p levels were not associated with event-free survival (P>0.05). In summary, miR-125b-5p may serve as a potential clinical biomarker for MM.

Serum miR-125b levels associated with epithelial ovarian cancer (EOC) development and treatment responses

“…In EOC, Zuberi and colleagues [17] demonstrated that serum levels of miR-125b were higher in most patients with cancer and were associated with cancer development, which could be a potential diagnostic and prognostic marker in clinical practice. More importantly, miR-125b may also have potential as a cancerspecific serum biomarker for various human cancers [19][20][21]. Other previous studies showed the enforced miR-125b had a potent antitumor activity in vitro and in vivo models of therapy against EOC [15,22,23].…”

Downregulation of miR‑136 promotes the progression of osteosarcoma and is associated with the prognosis of patients with osteosarcoma

“…Together, these previous studies suggested that identification of cancer-associated biomarkers for tumor progression and outcome may help to predict patient prognosis and treatment strategies. A number of miRNAs have been demonstrated to contribute to the development of cancer and to serve as biomarkers for the diagnosis, prognosis or treatment of different types of cancer (30)(31)(32). Taheriazam et al (33) demonstrated that miRNA-130b expression was increased in OS tissues, whereas, the level of miRNA-218 expression was downregulated; these miRNAs may serve as potential biomarkers in the early detection of OS.…”

Role of microRNAs in Diagnosis, Prognosis and Management of Multiple Myeloma

“…Serum analysis revealed a combination of up-regulated miR-34a and down-regulated let-7e could distinguish MM from control with a sensitivity and specificity of 80%, and MGUS with a sensitivity and specificity of over 90% ( Table 3 ) [ 183 ]. Other suggested markers include increased plasma miR-125b-5p, serum miR-29a, serum miR-4449, and decreased serum miR-30d and miR-203 levels [ 184 , 185 , 186 , 187 , 188 ]. In addition, the miR-125b-5p level was associated with extramedullary infiltration and was significantly higher in stage III patients compared to stage I/II patients [ 184 ].…”

“…Other suggested markers include increased plasma miR-125b-5p, serum miR-29a, serum miR-4449, and decreased serum miR-30d and miR-203 levels [ 184 , 185 , 186 , 187 , 188 ]. In addition, the miR-125b-5p level was associated with extramedullary infiltration and was significantly higher in stage III patients compared to stage I/II patients [ 184 ]. Similarly, plasma miR-483-5p level in MM patients was also found to be correlated with ISS stage [ 189 ].…”